Gieske T H, Sabol J S, Weintraub P M, Raddatz R, Cregge R J
Merrell Dow Research Institute, Cincinnati, Ohio.
Pharmacology. 1990;40(5):271-6. doi: 10.1159/000138672.
[(Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]acet ic acid (MDL 43,291) is a novel leukotriene (LT) receptor antagonist. It is a competitive antagonist of LTD4 (pA2 = 6.7) and LTE4 (pA2 = 6.7) and an apparent noncompetitive inhibitor of LTC4 ('pseudo' pA2 = 6.8) in the longitudinal muscle of the guinea pig ileum. At concentrations that effectively antagonize peptidoleukotriene-induced contractions, MDL 43,291 does not antagonize histamine, carbachol or substance P. In vivo, 10-30 mg/kg MDL 43,291, given intravenously, effectively inhibits increases in insufflation pressure induced by 100 ng/kg i.v. LTD4. This compound is a prototype of a novel class of leukotriene receptor antagonists that may be useful in the treatment of bronchial asthma and related disorders.
[(八氢-2-氧代-7-十四亚基-2H-1-苯并吡喃-8-基)硫代]乙酸(MDL 43,291)是一种新型白三烯(LT)受体拮抗剂。它是豚鼠回肠纵肌中LTD4(pA2 = 6.7)和LTE4(pA2 = 6.7)的竞争性拮抗剂,以及LTC4的明显非竞争性抑制剂('伪' pA2 = 6.8)。在有效拮抗肽白三烯诱导的收缩的浓度下,MDL 43,291不拮抗组胺、卡巴胆碱或P物质。在体内,静脉注射10 - 30 mg/kg MDL 43,291可有效抑制静脉注射100 ng/kg LTD4引起的吹入压力升高。该化合物是一类新型白三烯受体拮抗剂的原型,可能对治疗支气管哮喘及相关疾病有用。